- Home
- ZDAI vs LPCN Comparison
ZDAI vs LPCN Comparison
Compare ZDAI & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDAI
- LPCN
- Stock Information
- Founded
- ZDAI 2022
- LPCN 1997
- Country
- ZDAI Hong Kong
- LPCN United States
- Employees
- ZDAI N/A
- LPCN N/A
- Industry
- ZDAI General Bldg Contractors - Nonresidential Bldgs
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ZDAI Consumer Discretionary
- LPCN Health Care
- Exchange
- ZDAI Nasdaq
- LPCN Nasdaq
- Market Cap
- ZDAI 14.8M
- LPCN 13.8M
- IPO Year
- ZDAI 2024
- LPCN N/A
- Fundamental
- Price
- ZDAI $0.39
- LPCN $3.36
- Analyst Decision
- ZDAI
- LPCN Strong Buy
- Analyst Count
- ZDAI 0
- LPCN 1
- Target Price
- ZDAI N/A
- LPCN $7.00
- AVG Volume (30 Days)
- ZDAI 2.3M
- LPCN 55.2K
- Earning Date
- ZDAI 12-02-2025
- LPCN 11-06-2025
- Dividend Yield
- ZDAI N/A
- LPCN N/A
- EPS Growth
- ZDAI N/A
- LPCN N/A
- EPS
- ZDAI N/A
- LPCN N/A
- Revenue
- ZDAI $19,275,673.00
- LPCN $4,322,693.00
- Revenue This Year
- ZDAI N/A
- LPCN N/A
- Revenue Next Year
- ZDAI N/A
- LPCN N/A
- P/E Ratio
- ZDAI N/A
- LPCN N/A
- Revenue Growth
- ZDAI 43.16
- LPCN N/A
- 52 Week Low
- ZDAI $0.36
- LPCN $2.52
- 52 Week High
- ZDAI $107.36
- LPCN $5.50
- Technical
- Relative Strength Index (RSI)
- ZDAI 36.90
- LPCN 69.63
- Support Level
- ZDAI $0.45
- LPCN $2.80
- Resistance Level
- ZDAI $0.40
- LPCN $3.07
- Average True Range (ATR)
- ZDAI 0.04
- LPCN 0.19
- MACD
- ZDAI -0.00
- LPCN 0.07
- Stochastic Oscillator
- ZDAI 18.82
- LPCN 81.31
About ZDAI Primega Group Holdings Limited Ordinary Shares
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.